The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy

Proteomics - Clinical Applications

Volumn 8, Issue 3-4, 2014, Pages 218-231

  Semba, Richard D ^a   Huang, Hu ^a   Lutty, Gerard A ^a   Van Eyk, Jennifer E ^b   Hart, Gerald W ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Diabetic retinopathy; Glucose toxicity; Hexosamine biosynthesis pathway; O GlcNAcylation

Indexed keywords

HEXOSAMINE; N ACETYLGLUCOSAMINE; O LINKED BETA ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG; GLUCOSE; N ACETYLGLUCOSAMINYLTRANSFERASE; O-GLCNAC TRANSFERASE;

ACYLATION; ARTICLE; BIOSYNTHESIS; CORNEA; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLOMERULUS; GLUCOSE METABOLISM; HEART LEFT VENTRICLE; HUMAN; INSULIN RESISTANCE; KIDNEY TUBULE; LENS; NONHUMAN; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN MODIFICATION; RETINA; SIGNAL TRANSDUCTION; GENETICS; GLYCOSYLATION; HYPERGLYCEMIA; METABOLISM; PATHOLOGY; PROTEIN PROCESSING;

ACETYLGLUCOSAMINE; DIABETIC RETINOPATHY; GLUCOSE; GLYCOSYLATION; HUMANS; HYPERGLYCEMIA; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84898547546     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300076     Document Type: Article

References (133)

1. Yau, J. W., Roger, S. L., Kawasaki, R., Lamoureux, E. L. et al., Meta-analysis for Eye Disease (META-EYE) Study Group, global prevalence and major risk factors for diabetic retinopathy. Diabetes Care 2012, 35, 556-564.
2. Antonetti, D. A., Klein, R., Gardner, T. W., Diabetic retinopathy. N. Engl. J. Med. 2012, 366, 1227-1239.
3. Keech, A. C., Mitchell, P., Summanen, P. A., O'Day, J. et al., FIELD study investigators, effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370, 1687-1697.
4. ACCORD Study Group, ACCORD Eye Study Group, Chew, E. Y., Ambrosius, W. T. et al., Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 2010, 363, 233-244.
5. Michaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S. et al., A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010, 117, 1078.e2-1086.e2.
6. Rajendram, R., Fraser-Bell, S., Kaines, A., Michaelides, M. et al., A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch. Ophthalmol. 2012, 130, 972-979.
7. Nguyen, Q. E., Shah, S. M., Khwaja, A. A., Channa, R. et al., READ-2 study group, two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010, 117, 2146-2151.
8. Chaturvedi, N., Sjolie, A. K., Stephenson, J. M., Abrahamian, H. et al., Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 1998, 351, 28-31.
9. Sjolie, A. K., Klein, R., Porta, M., Orchard, T. et al., DIRECT Programme Study Group, Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008, 372, 1385-1393.
10. Chaturvedi, N., Porta, M., Klein, R., Orchard, T. et al., DIRECT Programme Study Group, effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372, 1394-1402.
11. Nathan, D. M., Zinman, B., Cleary, P. A., Backlund, J. Y. et al., DCCT/EDIC Research Group, modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes controls and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch. Intern. Med. 2009, 169, 1307-1316.
12. Gariano, R. F., Gardner, T. W., Retinal angiogenesis in development and disease. Nature 2005, 438, 960-966.
13. Copeland, R. J., Bullen, J. W., Hart, G. W., Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E17-E28.
14. Torres, C. R., Hart, G. W., Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 1984, 259, 3308-3317.
15. Vosseller, K., Trinidad, J. C., Chalkley, R. J., Specht, C. G. et al., O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol. Cell. Proteomics 2006, 5, 923-934.
16. Alfaro, J. F., Gong, C. X., Monroe, M. E., Aldrich, J. T. et al., Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc. Natl. Acad. Sci. 2012, 109, 7280-7285.
17. Nagel, A. K., Schilling, M., Comte-Walters, S., Berkaw, M. N., Ball, L. E., Identification of O-linked N-acetyleglucosamine (O-GlcNAc)-modified osteoblast proteins by electron transfer dissociation mass spectrometry reveals proteins critical for bone formation. Mol. Cell. Proteomics 2013, 12, 945-955.
18. Hahne, H., Sobotzki, N., Nyberg, T., Helm, D. et al., Proteome wide purification and identification of O-GlcNAc-modified proteins using click chemistry and mass spectrometry. J. Proteome Res. 2013, 12, 927-936.
19. Hart, G. W., Akimoto, Y., The O-GlcNAc modification., in: Varki, A., Cummings, R. D., Esko, J. D., Freeze, H. H., et al. (Eds.), Essentials of Glycobiology, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2009, pp. 263-280.
20. Zachara, N. E., Hart, G. W., Cell signaling, the essential role of O-GlcNAc! Biochim. Biophys. Acta 2006, 1761, 599-617.
21. Lazarus, M. B., Nam, Y., Jiang, J., Sliz, P., Walker, S., Structure of human O-GlcNAc transferase and its complex with a peptide structure. Nature 2011, 469, 564-567.
22. Kreppel, L. K., Blomberg, M. A., Hart, G. W., Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem. 1997, 272, 9308-9315.
23. Vocadlo, D. J., O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. Curr. Opin. Chem. Biol. 2012, 16, 488-497.
24. Butkinaree, C., Cheung, W. D., Park, S., Park, K. et al., Characterization of beta-N-acetylglucosaminidase cleavage by caspase-3 during apoptosis. J. Biol. Chem. 2008, 283, 23557-23566.
25. Comtesse, N., Maldener, E., Meese, E., Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. Biochem. Biophys. Res. Comm. 2001, 283, 634-640.
26. Keembiyehetty, C. N., Krzeslak, A., Love, D. C., Hanover, J. A., A lipid-droplet-targeted O-GlcNAcase isoform is a key regulator of the proteasome. J. Cell Sci. 2011, 124, 2851-2860.
27. Schimpl, M., Schüttelkopf, A. W., Borodkin, V. S., van Aalten, D. M., Human OGA binds substrates in a conserved peptide recognition groove. Biochem. J. 2010, 432, 1-7.
28. Schimpl, M., Borodkin, V. S., Gray, L. J., van Aalten, D. M., Synergy of peptide and sugar in O-GlcNAcase substrate recognition. Chem. Biol. 2012, 19, 173-178.
29. Marshall, S., Bacote, V., Traxinger, R. R., Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 1991, 266, 4706-4712.
30. Buse, M. G., Hexosamines, insulin resistance and the complications of diabetes: current status. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E1-E8.
31. Yi, W., Clark, P. M., Mason, D. E., Keenan, M. C. et al., Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012 337, 975-980.
32. Sánchez-Chávez, G., Peña-Rangel, M. T., Riesgo-Escovar, J. R., Martínez-Martínez, A., Salceda, R., Insulin stimulated-glucose transporter GLUT 4 is expressed in the retina. PLoS One 2012, 7, e52959.
33. Lu, L., Seidel, C. P., Iwase, T., Stevens, R. K. et al., Suppression of GLUT1; a new strategy to prevent diabetic complications. J. Cell Physiol. 2013; 228, 251-257.
34. Yki-Järvinen, H., Daniels, M. C., Virkamäki, A., Mäkimattila, S. et al., Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 1996, 45, 302-307.
35. Wang, Z., Park, K., Comer, F., Hsieh-Wilson, L. C. et al., Site-specific GlcNAcylation of human erythrocyte proteins: potential biomarker(s) for diabetes. Diabetes 2009, 58, 309-317.
36. Park, K., Saudek, C. D., Hart, G. W., Increased expression of beta-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes. Diabetes 2010, 59, 1845-1850.
37. Rossetti, L., Hawkins, M., Chen, W., Gindi, J., Barzilai, N., In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J. Clin. Invest. 1995, 96, 132-140.
38. Hawkins, M., Barzilai, N., Liu, R., Hu, M. et al., Role of the glucosamine pathway in fat-induced insulin resistance. J. Clin. Invest. 1997, 99, 2173-2182.
39. Vosseller, K., Wells, L., Lane, M. D., Hart, G. W., Elevated nucleocytoplastmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA 2002, 99, 5313-5318.
40. Whelan, S. A., Dias, W. B., Thiruneelakantapillai, L., Lane, M. D., Hart, G. W., Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-linked β-N-acetylglucosamine in 3T3-L1 adipocytes. J. Biol. Chem. 2010, 285, 5204-5211.
41. Penque, B. A., Hoggat, A. M., Herring, B. P., Elmendorf, J. S., Hexosamine biosynthesis impairs insulin action via a cholesterolgenic response. Mol. Endocrinol. 2013, 536-547.
42. Antonetti, D. A., Barber, A. J., Bronson, S. K., Freeman, W. M. et al., JDRF diabetic retinopathy center group, diabetic retinopathy: seeing beyond glucose-induce microvascular disease. Diabetes 2006, 55, 2401-2411.
43. Levy, A. P., Levy, N. S., Goldberg, M. A., Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 1996, 272, 2746-2753.
44. Murakami, T., Felinski, E. A., Antonetti, D. A., Occludin phosphorylation and ubiquination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 2009, 284, 21036-21046.
45. Sundstrom, J. M., Tash, B. R., Murakami, T., Flanagan, J. M. et al., Identification and analysis of occludin phosphosites: a combined mass spectrometry and bioinformatics approach. J. Proteome Res. 2009, 8, 808-817.
46. Harhaj, N. S., Felinski, E. A., Wolpert, E. B., Sundstrom, J. M. et al., VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci. 2006, 47, 5106-5115.
47. Mee, C. J., Farquhar, M. J., Harris, H. J., Hu, K. et al., Hepatitis C infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 2010, 138, 1134-1142.
48. Butt, A. M., Feng, D., Nasrullah, I., Tahir, S. et al., Computational identification of interplay between phosphorylation and O-β-glycosylation of human occludin as a potential mechanism to impair hepatitis C viral entry. Infect. Genet. Evol. 2012, 12, 1235-1245.
49. Huang, H., Gandhi, J. K., Zhong, X., Wei, Y. et al., TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest. Ophthalmol. Vis. Sci. 2011, 52, 1336-1344.
50. Joussen, A. M., Doehmen, S., Le, M. L., Koizumi, K. et al., TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15, 1418-1428.
51. Costa, G. N., Vindeirinho, J., Cavadas, C., Ambrósio, A. F., Santos, P. F., Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose. Mol. Cell. Neurosci. 2012, 50, 113-123.
52. Xing, D., Gong, K., Feng, W., Nozell, S. E. et al., O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS One 2011, 6, e24021.
53. Geraldes, P., Hiraoka-Yamamoto, J., Matsumoto, M., Clermont, A. et al., Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat. Med. 2009, 15, 1298-1306.
54. Matthews, J. A., Acevedo-Duncan, M., Potter, R. L., Selective decrease of membrane-associated PKC-alpha and PCK-epsilon in response to elevated intracellular O-GlcNAc levels in transformed human glial cells. Biochim. Biophys. Acta 2005, 1743, 305-315.
55. Robles-Flores, M., Meléndez, L., García, W., Mendoza-Hernández, G. et al., Posttranslational modifications on protein kinase C enzymes. Effects of epinephrine and phorbol esters. Biochim. Biophys. Acta 2008, 1783, 695-712.
56. Gao, B. B., Clermont, A., Rook, S., Fonda, S. J. et al., Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 2007, 13, 181-188.
57. Feener, E. P., Plasma kallikrein and diabetic macular edema. Curr. Diab. Rep. 2010, 10, 270-275.
58. Milne, R., Brownstein, S., Advanced glycation end products and diabetic retinopathy. Amino Acids 2013, 44, 1397-1407.
59. Berner, A. K., Brouwers, O., Pringle, R., Klaassen, I. et al., Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012, 55, 845-854.
60. Luo, D., Fan, Y., Xu, W., The effects of aminoguanidine on retinopathy in STZ-induced diabetic rats. Bioorg. Med. Chem. Lett. 2012, 22, 4386-4390.
61. Semba, R. D., Nicklett, E. J., Ferrucci, L., Does accumulation of advanced glycation end products contribute to the aging phenotype? J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 963-975.
62. Yamagishi, S., Hsu, C. C., Taniguchi, M., Harada, S. et al., Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun. 2004, 213, 681-687.
63. Liu, B., Bhat, M., Padival, A. K., Smith, D. G., Nagaraj, R. H., Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Invest. Ophthalmol. Vis. Sci. 2004, 45, 1983-1995.
64. Li, S. Y., Sigmon, V. K., Babcock, S. A., Ren, J., Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci. 2007, 80, 1051-1056.
65. Yao, D., Taguchi, T., Matsumura, T., Pestell, R. et al., High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J. Biol. Chem. 2007, 282, 31038-31045.
66. Frey, T., Antonetti, D. A., Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid. Redox Signal. 2011, 15, 1271-1284.
67. Roquemore, E. P., Dell, A., Morris, H. R., Panico, M. et al., Vertebrate lens α-crystallins are modified by O-linked N-acetylglucosamine. J. Biol. Chem. 1992, 267, 555-563.
68. Roquemore, E. P., Chevrier, M. R., Cotter, R. J., Hart, G. W., Dynamic O-GlcNAcylation of the small heat shock protein αB-cystallin. Biochemistry 1996, 35, 3578-3586.
69. Krishnamoorthy, V., Donofrio, A. J., Martin, J. L., O-GlcNAcylation of αB-crystallin regulates its stress-induced translocation and cytoprotection. Mol. Cell. Biol. 2013, 279, 59-68.
70. Wang, K., Ho, S. R., Mao, W., Huang, P. et al., Increased O-GlcNAc causes disrupted lens fiber cell differentiation and cataracts. Biochem. Biophys. Res Comm. 2009, 387, 70-76.
71. Abdelkader, H., Patel, D. V., McGhee, C. N. J., Alany, R. G., New therapeutic approaches in the treatment of diabetic keratopathy: a review. Clin. Exp. Ophthalmol. 2011, 39, 259-270.
72. Müller, L. J., Marfurt, C. F., Kruse, F., Tervo, T. M. T., Corneal nerves: structure, contents and function. Exp. Eye Res. 2003, 76, 521-542.
73. Akimoto, Y., Kawakami, H., Yamamoto, K., Munetomo, E. et al., Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats. Invest. Ophthalmol. Vis. Sci. 2003, 44, 3802-3809.
74. Patel, J. I., Tombran-Tink, J., Hykin, P. G., Gregor, Z. J., Cree, I. A., Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp. Eye Res. 2006, 82, 798-806.
75. Vinores, S. A., Derevjanik, N. L., Mahlow, J., Hackett, S. F. et al., Class III beta-tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes. Exp. Eye Res. 1995, 60, 385-400.
76. Chung, E. J., Chun, J. N., Jung, S. A., Cho, J. W., Lee, J. H., TGF-β-stimulated aberrant expression of class III β-tubulin via the ERK signaling pathway in cultured retinal pigment epithelial cells. Biochem. Biophys. Res. Comm. 2011, 415, 367-372.
77. Ji, S., Kang, J. G., Park, S. Y., Lee, J. H. et al., O-GlcNAcylation of tubulin inhibits its polymerization. Amino Acids 2011, 40, 809-818.
78. Ding, M., Vandré, D. D., High molecular weight microtubule-associated proteins contain O-linked-n-acetylglucosamine. J. Biol. Chem. 1996, 271, 12555-12561.
79. Arnold, C. S., Johnson, G. V., Cole, R. N., Dong, D. L. et al., The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J. Biol. Chem. 1996, 271, 28741-28744.
80. Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X. et al., A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 2008, 4, 483-490.
81. Gurel, Z., Sieg, K. M., Shallow, K. D., Sorenson, C. M., Sheibani, N., Retinal O-linked N-acetylglucosamine protein modifications: implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol. Vis. 2013, 19, 1047-1059.
82. Akita mouse as a model of early retinal complications in diabetes. Invest. Ophthalmol. Vis. Sci. 2005, 46, 2210-2218.
83. Akita diabetic mice. Invest. Ophthalmol. Vis. Sci. 2008, 49, 2635-2642.
84. Huang, H., Gandhi, J. K., Zhong, X., Wei, Y. et al., TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest. Ophthalmol. Vis. Sci. 2011, 52, 1336-1344.
85. Stahl, A., Connor, K. M., Sapieha, P., Chen, J. et al., The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 2010, 51, 2813-2826.
86. Semba, R. D., Enghild, J. J., Venkatramana, V., Dyrlund, T. F., Van Eyk, J. E., The human eye proteome project: perspectives on an emerging proteome. Proteomics 2013, 13, 2500-2511.
87. Hu Lab, Georgetown University. Available at http://cbsb.lombardi.georgetown.edu/hulab/OGAP.html, accessed July 4, 2013.
88. Wang, Z., Udeshi, N. D., Slawson, C., Compton, P. D. et al., Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesis. Sci. Signal. 2010, 3, ra2.
89. Schleicher, E. D., Weigert, C., Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int. Suppl. 2000, 77, S13-S18.
90. Weigert, C., Friess, U., Brodbeck, K., Häring, H. U., Schleicher, E. D., Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells. Diabetologia 2003, 46, 852-855.
91. Degrell, P., Cesh, J., Mohá, M., Molnár, G. A. et al., Evidence of O-linked N-acetylglucosamine in diabetic nephropathy. Life Sci. 2009, 84, 389-393.
92. Goldberg, H., Whiteside, C., Fantus, I. G., O-linked β-N-acetylglucosamine supports p38 MAPK activation by high glucose in glomerular mesangial cells. Am. J. Physiol. Endocrinol. Metab. 2011, 301, E713-E726.
93. Lunde, I. G., Aronsen, J. M., Kvaloy, H., Qvigstad, E. et al., Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol. Genomics 2012, 44, 162-172.
94. McLarty, J. L., Marsh, S. A., Chatham, J. C., Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci. 2013, 92, 621-627.
95. Marsh, S. A., Dell'Italia, L. J., Chatham, J. C., Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyoctes from diabetic mice. Amino Acids 2011, 40, 819-828.
96. Holt, G. D., Hart, G. W., The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J. Biol. Chem. 1986, 261, 8049-8057.
97. Hart, G. W., Slawson, C., Ramirez-Correa, G., Lagerlof, O., Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 2011, 80, 825-858.
98. Zachara, N. E., Vosseller, K., Hart, G. W., Detection and analysis of proteins modified by O-linked N-acetylglucosamine. Curr. Protoc. Mol. Biol. 2011, 17, 6.
99. Wang, Z., Hart, G. W., Glycomic approaches to study GlcNAcylation: protein identification, site-mapping, and site-specific O-GlcNAc quantitation. Clin. Proteomics 2008, 4, 5-13.
100. Comer, F. I., Vosseller, K., Wells, L., Accavitti, M. A., Hart, G. W., Characterization of mouse monoclonal antibody specific for O-linked N-acetylglucosamine. Anal. Biochem. 2001, 293, 169-177.
101. Holt, G. D., Snow, C. M., Senior, A., Haltiwanger, R. S. et al., Nuclear pore complex glycoproteins contain cytoplasmically disposed O-linked N-acetylglucosamine. J. Cell Biol. 1987, 104, 1157-1164.
102. Teo, C. F., Ingale, S., Wolfert, M. A., Elsayed, G. A. et al., Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAc. Nat. Chem. Biol. 2010, 6, 338-343.
103. Kamemura, K., Hayes, B. K., Comer, F. I., Hart, G. W., Dynamic interplay between O-glycosylation and O-phophorylation of nucleocytoplasmic proteins. Alternative glycosylation/phosphorylation of Thr58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J. Biol. Chem. 2002, 277, 19229-19235.
104. Pathak, S., Borodkin, V. S., Albarbarawi, O., Campbell, D. G. et al., O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release. EMBO J. 2012, 31, 1393-1404.
105. Yuzwa, S. A., Yadav, A. K., Skorobogatko, Y., Clark, T. et al., Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody. Amino Acids 2011, 40, 857-868.
106. Wang, Z., Udeshi, N., O'Malley, M., Shabanowitz, J. et al., Highly specific enrichment and site-mapping of O-GlcNAcylation using chemoenzymatic tagging, solid-phase photocleavage, and electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 2010, 9, 153-160.
107. Vosseller, K., Trinidad, J. C., Chalkley, R. J., Specht, C. G. et al., O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol. Cell. Proteomics 2006, 5, 923-834.
108. Trinidad, J. C., Barkan, D. T., Gulledge, B. F., Thalhammer, A. et al., Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol. Cell. Proteomics 2012, 11, 215-229.
109. Khidekel, N., Arndt, S., Lamarre-Vincent, N., Lippert, A. et al., A chemoenzymatic approach toward the rapid and sensitive detection of O-GlcNAc posttranslational modifications. J. Am. Chem. Soc. 2003, 125, 16162-16163.
110. Hahne, H., Sobotzki, N., Nyberg, T., Helm, D. et al., Proteome wide purification and identification of O-GlcNAc-modified proteins using click chemistry and mass spectrometry. J. Proteome Res. 2013, 12, 927-936.
111. Wells, L., Vosseller, K., Cole, R. N., Cronshaw, J. M. et al., Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol. Cell. Proteomics 2002, 1, 791-804.
112. Macauley, M. S., Vocadlo, D. J., Increasing O-GlcNAc levels: an overview of small-molecule inhibitors of O-GlcNAcase. Biochim. Biophys. Acta 2010, 1800, 107-121.
113. Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X. et al., A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 2008, 4, 483-490.
114. Dorfmueller, H. C., Borodkin, V. S., Schimpl, M., Shepherd, S. M. et al., GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels. J. Am. Chem. Soc. 2006, 128, 16484-16485.
115. Arias, E. B., Kim, J., Cartee, G. D., Prolonged incubation in PUGNAc results in increased protein O-linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes 2004, 53, 921-930.
116. Park, S. Y., Ryu, J., Lee, W., O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp. Mol. Med. 2005, 37, 220-229.
117. Gross, B. J., Kraybill, B. C., Walker, S., Discovery of O-GlcNAc transferase inhibitors. J. Am. Chem. Soc. 2005, 127, 14588-14589.
118. Gloster, T. M., Zandberg, W. F., Heinonen, J. E., Shen, D. L. et al., Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat. Chem. Biol. 2011, 7, 174-181.
119. Dorfmueller, H. C., Borodkin, V. S., Blair, P. E., Pathak, S. et al., Substrate and product analogues as human O-GlcNAc transferase inhibitors. Amino Acids 2011, 40, 781-792.
120. Lenzen, S., Panten, U., Alloxan: history and mechanism of action. Diabetologia 1988, 31, 337-342.
121. Housley, M. P., Rodgers, J. T., Udeshi, N. D., Kelly, T. J. et al., O-GlcNAc regulates FOXO activation in response to glucose. J. Biol. Chem. 2008, 283, 16283-16292.
122. Jensen, R. V., Zachara, N. E., Nielsen, P. H., Kimose, H. H. et al., Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc. Res. 2013, 97, 369-378.
123. Majumdar, G., Harmon, A., Candelaria, R., Martinez-Hernandez, A. et al., O-glycosylation of Sp1 and transcriptional regulation of the calmodulin gene by insulin and glucagon. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E584-E591.
124. Liu, J., Marchase, R. B., Chatham, J. C., Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J. Mol. Cell. Cardiol. 2007, 27, 177-185.
125. Hart, G. W., Slawson, C., Ramirez-Correa, G., Lagerlof, O., Crosstalk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription and chronic disease. Ann. Rev. Biochem. 2011, 80, 825-858.
126. Cheung, W. D., Sakabe, K., Housley, M. P., Dias, W. B., Hart, G. W., O-GlcNAc transferase substrate specificity is regulated by MYPT1 and other interacting proteins. J. Biol. Chem. 2008, 283, 33935-33941.
127. Housley, M. P., Rodgers, J. T., Puigserver, P., Hart, G. W., A PGC-1α-O-GlcNAc transferase regulates FOXO transcription factor activity in response to glucose. J. Biol. Chem. 2009, 284, 5148-5157.
128. Cheung, W. D., Hart, G. W., AMP-activated protein kinase and p38 activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J. Biol. Chem. 2008, 283, 13009-13020.
129. Al-Dhaheri, M. H., Rowan, B. G., Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha. Nucl. Recept. Signal. 2006, 4, e007.
130. Noren, C. J., Anthony-Cahill, S. J., Griffith, M. C., Schultz, P. G., A general method for site-specific incorporation of unnatural amino acids into proteins. Science 1989, 244, 182-188.
131. Muir, T. W., Sondhi, D., Cole, P. A., Expressed protein ligation: a general method for protein engineering. Proc. Natl. Acad. Sci. USA 1998, 95, 6705-6710.
132. Carrillo, L. D., Krishnamoorthy, L., Mahal, L. K., A cellular FRET-based sensor for beta-O-GlcNAc, a dynamic carbohydrate modification involved in signaling. J. Am. Chem. Soc. 2006, 128, 14768-14769.
133. Carrillo, L. D., Froemming, J. A., Mahal, L. K., Targeted in vivo O-GlcNAc sensors reveal discrete compartment-specific dynamics during signal transduction. J. Biol. Chem. 2011, 286, 6650-6658.